跳至主要内容
临床试验/CTRI/2019/06/019792
CTRI/2019/06/019792已完成2/3 期

A randomized controlled, single blind clinical trial for safety and efficacy of grassroots leads in the management of Osteopenia / Osteoporosis among postmenopausal women

National innovation foundation1 个研究点 分布在 1 个国家目标入组 360 人开始时间: 2019年1月7日最近更新:

试验速览

阶段
2/3 期
状态
已完成
入组人数
360
试验地点
1
主要终点
To compare the safety and efficacy of Grassroots leads with Ayurvedic drug (Lakshadi Guggulu and Praval Pishti) and Allopathic drug(Shalcal) in subject with postmenopausal osteoporosis.

研究概览

简要总结

This randomized multi arm controlled, single blind clinical trial was done for safety and efficacy of two grassroots leads  in the management of osteopenia/ osteoporosis among postmenopausal women. Two grassroots leads in two different formulation and in two different doses were compared against standard Ayurvedic drug and standard allopathic drug.Each group was given one year of medication.

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Participant Blinded

入排标准

年龄范围
40.00 Year(s) 至 70.00 Year(s)(—)
性别
Female

入选标准

  • 1.Postmenopausal women, defined as no menstruation for the last 12 months.
  • B.M.D.T. Score -1 to -3.5 at hip, spine and forearm (worst score at any of the three sites to be considered).

排除标准

  • score above -1 and less than -3.5
  • All women who are consuming any drug which is known to affect bone metabolism in doses for e.g. SERMs, bisphophonates, calcitonin, Vit.
  • D more than 60,000 units and corticosteroids more than 5mg/day for more than 3 months, methotrexate, anticonvulsants and diuretics.
  • Patients suffering from congenital disorders (Dysosteogenesis and Marfan.s Syndrome)
  • Patients with endocrine disorders (Hyperthyroidism, hyperparathyroidism, Untreated Cushing.s syndrome)
  • Patients with evidence of malignancy
  • Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Epilepsy)
  • Patients suffering from chronic hepatic disorder, renal failure or cardiac dysfunction.
  • Patient suffering from uncontrolled DM-2 or uncontrolled hypertension.
  • Patients suffering from Osteomalacia.
  • Patients suffering from Malabsorption syndrome
  • Patients undergone Organ transplantation or on immunosuppressive therapy
  • Prolonged immobilization
  • Patients whose Serum Ca++ level < 2.2 or > 2.6 mmol/L (< 9 or >10.5 mg/dL)
  • History of renal stones
  • Long bone fracture in last 6 months.
  • Patient not ready to give an informed consent
  • Subjects who has participated in any other clinical study in last 30 days.
  • Patients with clinical evidence of active and chronic illness as rheumatoid arthritis, gout,SLE, Psoriatic arthritis.

结局指标

主要结局

To compare the safety and efficacy of Grassroots leads with Ayurvedic drug (Lakshadi Guggulu and Praval Pishti) and Allopathic drug(Shalcal) in subject with postmenopausal osteoporosis.

时间窗: 1 year

次要结局

  • To assess the biomarker response for bone formation of study drugs in postmenopausal osteoporosis
  • Mean changes in quality of life among women suffering from postmenopausal osteoporosis(1 year)

研究者

申办方类型
Research institution

研究点 (1)

Loading locations...

相似试验